WO2015066057A3 - Expansion of cmv-specific t cells from cmv-seronegative donors - Google Patents

Expansion of cmv-specific t cells from cmv-seronegative donors Download PDF

Info

Publication number
WO2015066057A3
WO2015066057A3 PCT/US2014/062698 US2014062698W WO2015066057A3 WO 2015066057 A3 WO2015066057 A3 WO 2015066057A3 US 2014062698 W US2014062698 W US 2014062698W WO 2015066057 A3 WO2015066057 A3 WO 2015066057A3
Authority
WO
WIPO (PCT)
Prior art keywords
cmv
cells
seronegative
specific
expansion
Prior art date
Application number
PCT/US2014/062698
Other languages
French (fr)
Other versions
WO2015066057A2 (en
Inventor
Catherine BOLLARD
Patrick Hanley
Original Assignee
Baylor College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Of Medicine filed Critical Baylor College Of Medicine
Publication of WO2015066057A2 publication Critical patent/WO2015066057A2/en
Publication of WO2015066057A3 publication Critical patent/WO2015066057A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Embodiments of the disclosure include methods and compositions for adoptive transfer using naive T-cells. In particular embodiments, the naive T-cells are cord blood cells or are seronegative in relation to a particular virus. In specific embodiments, the naive T-cells are CMV-seronegative and are processed to be useful for recipients of any kind, including CMV- seronegative or CMV-seropositive recipients.
PCT/US2014/062698 2013-10-28 2014-10-28 Expansion of cmv-specific t cells from cmv-seronegative donors WO2015066057A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361896296P 2013-10-28 2013-10-28
US61/896,296 2013-10-28

Publications (2)

Publication Number Publication Date
WO2015066057A2 WO2015066057A2 (en) 2015-05-07
WO2015066057A3 true WO2015066057A3 (en) 2015-11-19

Family

ID=53005364

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/062698 WO2015066057A2 (en) 2013-10-28 2014-10-28 Expansion of cmv-specific t cells from cmv-seronegative donors

Country Status (1)

Country Link
WO (1) WO2015066057A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016154112A1 (en) * 2015-03-20 2016-09-29 Children's National Medical Center Generating virus or other antigen-specific t cells from a naive t cell population
WO2018213192A1 (en) 2017-05-15 2018-11-22 University Of Miami Materials and methods for subjects at risk for viral reactivation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029571A1 (en) * 2008-05-14 2010-02-04 Immatics Biotechnologies Gmbh Novel and powerful mhc-class ii peptides derived from survivin
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
US20120225820A1 (en) * 2003-03-07 2012-09-06 London Health Sciences Centre Research Inc. Peptides associated with hla-dr mhc class ii molecule and involved in rheumatoid arthritis
US20130101594A1 (en) * 2007-03-29 2013-04-25 Technion Research & Development Foundation Ltd. Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225820A1 (en) * 2003-03-07 2012-09-06 London Health Sciences Centre Research Inc. Peptides associated with hla-dr mhc class ii molecule and involved in rheumatoid arthritis
US20130101594A1 (en) * 2007-03-29 2013-04-25 Technion Research & Development Foundation Ltd. Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
US20100029571A1 (en) * 2008-05-14 2010-02-04 Immatics Biotechnologies Gmbh Novel and powerful mhc-class ii peptides derived from survivin
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring

Also Published As

Publication number Publication date
WO2015066057A2 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
WO2011094572A3 (en) Hanging drop devices, systems and/or methods
EP3303635A4 (en) Compositions and methods for screening t cells with antigens for specific populations
IL248451A0 (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
WO2016094839A3 (en) Compositions and methods for performing methylation detection assays
MX2021008142A (en) Methods for harvesting mammalian cell cultures.
MX370018B (en) Improved methods for manufacturing adoptive cell therapies.
WO2015071474A3 (en) Crispr-cas system materials and methods
WO2015188106A3 (en) Perfusion culturing methods and uses thereof
SG195306A1 (en) Purification of biological products by constrained cohydration chromatography
EP2614140B8 (en) Mdck-derived cell lines adapted to serum-free culture and suspension culture and method for preparing vaccine virus using the cells
MX354267B (en) Modified nucleosides, nucleotides, and nucleic acids, and uses thereof.
WO2016196912A8 (en) Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
WO2013166338A3 (en) Cell capture system and use thereof
CA2866116C (en) Expansion of alloantigen-reactive regulatory t cells
EP3458572A4 (en) Human stem cell derived endothelial cells, endothelial- hepatocyte co-culture system and uses thereof
WO2015058132A3 (en) Anti-rsp02 and/or anti-rsp03 antibodies and their uses
EP3248237A4 (en) Solid buffer materials for electrolyte solutions and flow batteries utilizing same
EP3060648A4 (en) Systems, devices and methods for microfluidic culturing, manipulation and analysis of tissues and cells
EP3489351A4 (en) Cell cultivation method, suspended cell elimination method, and method to kill suspended cells
WO2014140921A3 (en) Cells, methods and apparatuses for umbilical cord blood collection and isolation of cells
HK1224333A1 (en) Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
MX366112B (en) Cell culture media and methods of antibody production.
EP3697895A4 (en) Systems and methods to produce b cells genetically modified to express selected antibodies
EP3007710A4 (en) Cell populations, methods of transdifferention and methods of use thereof
WO2015171852A3 (en) Methods and compositions for non-cytotoxic stem cell transplantation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14858363

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14858363

Country of ref document: EP

Kind code of ref document: A2